351 related articles for article (PubMed ID: 34985936)
1. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
Pellini B; Chaudhuri AA
J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
[TBL] [Abstract][Full Text] [Related]
2. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments.
Oh Y; Yoon SM; Lee J; Park JH; Lee S; Hong T; Chung LI; Sudhaman S; Riddell T; Palsuledesai CC; Krainock M; Liu MC; Chae YK
Thorac Cancer; 2024 May; 15(13):1095-1102. PubMed ID: 38558374
[TBL] [Abstract][Full Text] [Related]
3. ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approach.
Nielsen LR; Stensgaard S; Meldgaard P; Sorensen BS
Cancer Treat Res Commun; 2024; 39():100802. PubMed ID: 38428066
[TBL] [Abstract][Full Text] [Related]
4. Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer.
Waldeck S; Mitschke J; Wiesemann S; Rassner M; Andrieux G; Deuter M; Mutter J; Lüchtenborg AM; Kottmann D; Titze L; Zeisel C; Jolic M; Philipp U; Lassmann S; Bronsert P; Greil C; Rawluk J; Becker H; Isbell L; Müller A; Doostkam S; Passlick B; Börries M; Duyster J; Wehrle J; Scherer F; von Bubnoff N
Mol Oncol; 2022 Jan; 16(2):527-537. PubMed ID: 34653314
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer.
Tan AC; Lai GGY; Saw SPL; Chua KLM; Takano A; Ong BH; Koh TPT; Jain A; Tan WL; Ng QS; Kanesvaran R; Rajasekaran T; Kalashnikova E; Renner D; Sudhaman S; Malhotra M; Sethi H; Liu MC; Aleshin A; Lim WT; Tan EH; Skanderup AJ; Ang MK; Tan DSW
Cancer; 2024 May; 130(10):1758-1765. PubMed ID: 38422026
[TBL] [Abstract][Full Text] [Related]
6. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.
Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N
Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155
[TBL] [Abstract][Full Text] [Related]
7. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.
Qiu B; Guo W; Zhang F; Lv F; Ji Y; Peng Y; Chen X; Bao H; Xu Y; Shao Y; Tan F; Xue Q; Gao S; He J
Nat Commun; 2021 Nov; 12(1):6770. PubMed ID: 34799585
[TBL] [Abstract][Full Text] [Related]
8. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
[TBL] [Abstract][Full Text] [Related]
9. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer.
Li FQ; Cui JW
Crit Rev Oncol Hematol; 2022 Nov; 179():103800. PubMed ID: 36031171
[TBL] [Abstract][Full Text] [Related]
11. Circulating tumor DNA minimal residual disease in clinical practice of non-small cell lung cancer.
Xia J; Zhang J; Xiong Y; Zhao J; Zhou Y; Jiang T; Zhu J
Expert Rev Mol Diagn; 2023; 23(10):913-924. PubMed ID: 37702546
[TBL] [Abstract][Full Text] [Related]
12. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
13. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.
Abbosh C; Birkbak NJ; Swanton C
Nat Rev Clin Oncol; 2018 Sep; 15(9):577-586. PubMed ID: 29968853
[TBL] [Abstract][Full Text] [Related]
14. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer.
Bossé Y; Dasgupta A; Abadier M; Guthrie V; Song F; Saavedra Armero V; Gaudreault N; Orain M; Lamaze FC; Melton C; Nance T; Hung T; Hodgson D; Abbosh C; Joubert P
Cancer Lett; 2024 Jul; 594():216984. PubMed ID: 38797230
[TBL] [Abstract][Full Text] [Related]
16. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
17. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
[TBL] [Abstract][Full Text] [Related]
18. The Role and Impact of Minimal Residual Disease in NSCLC.
Frisone D; Friedlaender A; Addeo A
Curr Oncol Rep; 2021 Nov; 23(12):136. PubMed ID: 34735646
[TBL] [Abstract][Full Text] [Related]
19. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Ricciuti B; Jones G; Severgnini M; Alessi JV; Recondo G; Lawrence M; Forshew T; Lydon C; Nishino M; Cheng M; Awad M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771889
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of minimal residual disease detection by circulating tumor DNA profiling in lung cancer: a meta-analysis.
Zhong R; Gao R; Fu W; Li C; Huo Z; Gao Y; Lu Y; Li F; Ge F; Tu H; You Z; He J; Liang W
BMC Med; 2023 May; 21(1):180. PubMed ID: 37173789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]